ZetaGen Therapeutics Email Format

Pharmaceutical ManufacturingNew York, United States2-10 Employees

Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company based in Syracuse, New York, operating from the Central New York Biotech Accelerator. It develops intratumoral therapies for metastatic and primary breast cancer, using proprietary carriers to deliver tumoricidal treatment in a single injection with the goal of reducing off-target effects and potentially improving survival. The company maintains an extensive IP portfolio with more than 70 issued patents, including composition-of-matter patents, and has earned FDA Breakthrough Designations since its founding in 2015.

Its pipeline includes ZetaMet for bone metastases, ZetaMast for liver metastases, and ZetaPrime for primary breast cancer, with Phase 2a results reported for the lead candidate. A Phase 2a study at the University of British Columbia reported complete bone response and regeneration with no skeletal-related events, and peer-reviewed publications have documented clinical efficacy.

Sign up for free to view info

Company overview Employee directory